Premarket Movers: Ross Stores, Apellis Pharmaceuticals, Palo Alto Networks Premarket Movers: Ross Stores, Apellis Pharmaceuticals, Palo Alto Networks...…
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA) WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and…
Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
5 Analysts Have This to Say About Apellis Pharmaceuticals Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter: Latest Ratings for APLS …
Insiderhandel: Chief Commercial Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 292.700$ Townsend, Adam J. - Vorstand - Tag der Transaktion: 2022-11-03...…
Form 10-Q Apellis Pharmaceuticals, For: Sep 30 Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Apellis Pharmaceuticals Q3 2022 Earnings Preview Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Is a Surprise Coming for Apellis (APLS) This Earnings Season? Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH) Robust…
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Insiderhandel: Aufsichtsrat verkauft Aktien von Apellis Pharmaceuticals im Wert von 74.138$ Machiels, Alec - Aufsichtsrat - Tag der Transaktion: 2022-10-14...…
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Insiderhandel: CHIEF MEDICAL OFFICER verkauft Aktien von Apellis Pharmaceuticals im Wert von 166.725$ Grossi, Federico - Vorstand - Tag der Transaktion: 2022-10-03...…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 333.450$ Townsend, Adam J. - Vorstand - Tag der Transaktion: 2022-10-03...…